IMV Inc (IMV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7987
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
IMV Inc (IMV), formerly Immunovaccine Inc, is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and infectious disease vaccines. The company’s product candidates include DPX-Survivac, a T cell activating immunotherapy that identifies and disrupts cancer biology in solid and hematological cancers; DPX-E7, an investigational immunotherapy that targets a viral protein in human papillomavirus in cervical and related cancers; and DPX-RSV, a lead infectious disease candidate is a small B cell epitope peptide vaccine intended to address the needs in respiratory syncytial virus. The company partners with various universities, research institutes and other vaccine development companies to develop its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.

IMV Inc (IMV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
Equity Offering 19
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 29
Immunovaccine Completes Private Placement Of Shares For US$4 Million 30
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 33
IMV Inc – Key Competitors 34
IMV Inc – Key Employees 35
IMV Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Strategy And Business Planning 37
Sep 04, 2018: IMV Celebrates Grand Opening of New Facility in Dartmouth, Nova Scotia 37
Financial Announcements 38
Aug 08, 2018: IMV announces Q2 2018 financial results 38
May 14, 2018: IMV Announces Q1 2018 Financial Results 40
Mar 20, 2018: Immunovaccine Announces Year-End 2017 Financial Results 42
Nov 09, 2017: Immunovaccine Announces Third Quarter 2017 Financial Results 44
Aug 08, 2017: Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017 45
May 10, 2017: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017 47
Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 48
Corporate Communications 51
Jun 07, 2018: IMV Appoints Julia P. Gregory to Board of Directors 51
May 31, 2018: Nasdaq Approves Listing of IMV Common Shares 52
Jan 18, 2018: Immunovaccine Appoints Joseph Sullivan as Senior Vice President of Business Development 53
Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 54
Product News 55
Jan 31, 2018: Published Study Demonstrates the Association Between Immunovaccine’s Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression 55
Clinical Trials 56
Oct 05, 2017: Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Companys DepoVax-based Programs 56
Apr 12, 2017: Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate 57
Other Significant Developments 58
May 10, 2018: IMV – Change of ticker on OTCQX from IMMVF to IMMVD 58
Aug 08, 2017: Immunovaccine Issues Second Quarter 2017 Letter to Shareholders 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
IMV Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Deals By Therapy Area, 2012 to YTD 2018 9
IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
IMV Enters into Partnership with Merck 11
PCI Biotech Enters into Agreement with IMV 12
Immunovaccine Enters into Agreement with Incyte 13
Immunovaccine Enters into Agreement with University of Edinburgh 14
Immunovaccine Extends Partnership with UConn Health 15
Immunovaccine Expands Agreement with Leidos 16
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 17
ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 18
IMV Plans to Raise up to USD150 Million in Public Offering of Securities 19
Immunovaccine Raises USD11.6 Million in Public Offering of Shares 20
Immunovaccine Raises USD7.4 Million in Public Offering of Shares 21
Immunovaccine Raises USD6 Million in Private Placement of Shares 22
Immunovaccine Raises USD6.2 Million in Private placement of Units 23
Immunovaccine Raises USD8.7 Million in Public Offering of Units 25
Immunovaccine Raise USD1.58 Million in Private Placement of Shares 27
Immunovaccine Withdraws Prospectus For Public Offering Of Shares For US$6.8 Million 28
Immunovaccine Withdraws Private Placement Of Shares For US$1 Million 29
Immunovaccine Completes Private Placement Of Shares For US$4 Million 30
Immunovaccine Completes Private Placement Of Units For US$1.6 Million 31
Immunovaccine Completes Private Placement Of Common Stock For US$2.8 Million 33
IMV Inc, Key Competitors 34
IMV Inc, Key Employees 35
IMV Inc, Other Locations 36

List of Figures
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[IMV Inc (IMV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OGD2 Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary OGD2 Pharma SAS (OGD2 Pharma) is an independent pre-clinical stage biotechnology company that researches, develops and commercializes cancer immunotherapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2). The company pipeline product portfolio includes OGD201, a humanized mo …
  • Penta-Ocean Construction Co Ltd:戦略・SWOT・企業財務分析
    Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Penta-Ocean Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Carmot Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carmot Therapeutics Inc (Carmot Therapeutics) is a biotechnology company that discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. The company provides product portfolio such as encompasses investigational candidates in preclinical trials: peptide-sm …
  • Hermes Europe GmbH:企業の戦略的SWOT分析
    Hermes Europe GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • National Reinsurance Corporation Of The Philippines
    National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report Summary National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • BioMark Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary BioMark Diagnostics Inc (BioMark Diagnostics) is an oncology-focused medical equipment company that owns and develops multiple intellectual properties in detection and quantitation of metabolites. The company’s advanced near-to- market diagnostic technologies designed to improve patient outc …
  • International Drug Development Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical serv …
  • Apollo Global Management Inc:企業の戦略・SWOT・財務分析
    Apollo Global Management Inc - Strategy, SWOT and Corporate Finance Report Summary Apollo Global Management Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GrowMax Resources Corp (BOE):企業の財務・戦略的SWOT分析
    Summary GrowMax Resources Corp (GrowMax), formerly Americas Petrogas Inc is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas properties in Argentina. The company explores and develops phosphate and potassium-rich brine resources in northwe …
  • RXi Pharmaceuticals Corporation:企業のM&A・事業提携・投資動向
    RXi Pharmaceuticals Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RXi Pharmaceuticals Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Medidata Solutions Inc (MDSO)-医療機器分野:企業M&A・提携分析
    Summary Medidata Solutions Inc (Medidata) is a provider of cloud based solutions for life sciences sectors. It offers wide range of advanced tools for data & analytics, planning, data capture, study management, monitoring, payments, and platform services. The company offers technology and data analy …
  • Yoho Resources Inc. (YO)-石油・ガス分野:企業M&A・提携分析
    Summary Yoho Resources Inc. (Yoho) is an upstream oil and gas exploration company. The company carries out exploration, development and production of crude oil and natural gas liquid, and natural gas. The company has operations within the Western Canadian Sedimentary Basin focusing exploration activ …
  • Miromatrix Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a biotechnology company engaged in the development extracellular matrix based medical devices in soft tissue reinforcement and advanced wound care. The company offers MIRODERM a porcine liver-derived noncrosslinked acellular biologic wound matri …
  • Kootenai Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Kootenai Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • China Gas Holdings Ltd (384):企業の財務・戦略的SWOT分析
    China Gas Holdings Ltd (384) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Eng Kah Corporation Berhad:企業の戦略・SWOT・財務情報
    Eng Kah Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Eng Kah Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dyadic International Inc (DYAI):企業の財務・戦略的SWOT分析
    Summary Dyadic International Inc (Dyadic) is a biotechnology company that develops, discovers, manufactures, and commercializes protein-based drugs. The company utilizes its patented and proprietary technology Myceliopthora thermophila expression systems to conduct research and produce industrial en …
  • Aspect Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aspect Imaging Inc (Aspect Imaging) is a medical device company that develops and manufactures magnetic resonance imaging systems. The company’s products comprise wristview medical systems, preclinical, process control, oil and gas analyzers, NMR, materials MRI and software. It offers precli …
  • Livzon Pharmaceutical Group Co Ltd (000513):企業の財務・戦略的SWOT分析
    Summary Livzon Pharmaceutical Group Co Ltd (Livzon) a subsidiary of Joincare Pharmaceutical Group Industry Co Ltd, is a pharmaceutical company which is engaged in developing, manufacturing and distributing pharmaceutical products. The company provides preparation drug products, bulk medicines and in …
  • Norgine BV:企業の戦略的SWOT分析
    Norgine BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆